Cancer-Associated Hypercalcemia

Abstract

Cancer-Associated Hypercalcemia (N Engl J Med 2022;386:1443-1451). In the legend for Figure 1 (page 1444), the spellout for RANKL should have been “receptor activator of nuclear factor κB ligand,” rather than “anti–receptor activator ….” In Table 1 (page 1447), the third column head should have been “Local Osteolytic Hypercalcemia,” rather than “… Hypocalemia.” In the column below “Parathyroid hormone,” the value in the PTHrP row should have been “Low,” rather than “High.” In the Conclusions and Recommendations section (page 1450), the first sentence should have ended, “… indicate that the cancer-associated hypercalcemia has a humoral cause,” rather than “… indicate that the cancer has a humoral cause.” . . .